Search

Your search keyword '"Krueger, James G."' showing total 1,548 results
Start Over Author "Krueger, James G."
1,548 results on '"Krueger, James G."'

205. Cover Image

Author

Frew, John, primary, Penzi, Lauren, additional, Suarez‐Farinas, Mayte, additional, Garcet, Sandra, additional, Brunner, Patrick M., additional, Czarnowicki, Tali, additional, Kim, Jaehwan, additional, Bottomley, Claire, additional, Finney, Robert, additional, Cueto, Inna, additional, Fuentes‐Duculan, Judilyn, additional, Ohmatsu, Hanako, additional, Lentini, Tim, additional, Yanofsky, Valerie, additional, Krueger, James G., additional, Guttman‐Yassky, Emma, additional, and Gareau, Daniel, additional

Published
2021
Full Text
View/download PDF

207. Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial

Author

Gordon, Kenneth B, primary, Foley, Peter, additional, Krueger, James G, additional, Pinter, Andreas, additional, Reich, Kristian, additional, Vender, Ronald, additional, Vanvoorden, Veerle, additional, Madden, Cynthia, additional, White, Katy, additional, Cioffi, Christopher, additional, and Blauvelt, Andrew, additional

Published
2021
Full Text
View/download PDF

209. Pathogenesis and therapy of psoriasis

Author

Lowes, Michelle A., Bowcock, Anne M., and Krueger, James G.

Subjects
Environmental issues, Science and technology, Zoology and wildlife conservation
Abstract

Author(s): Michelle A. Lowes [1]; Anne M. Bowcock [2]; James G. Krueger [1] Psoriasis is a common skin disease that has been recognized since ancient times, when it was erroneously [...]

Published
2007
Full Text
View/download PDF

211. Enhancement of cutaneous immunity during aging by blocking p38 mitogen-activated protein (MAP) kinase–induced inflammation

Author

Vukmanovic-Stejic, Milica, Chambers, Emma S., Suárez-Fariñas, Mayte, Sandhu, Daisy, Fuentes-Duculan, Judilyn, Patel, Neil, Agius, Elaine, Lacy, Katie E., Turner, Carolin T., Larbi, Anis, Birault, Veronique, Noursadeghi, Mahdad, Mabbott, Neil A., Rustin, Malcolm H.A., Krueger, James G., and Akbar, Arne N.

Subjects
Adult, CD4-Positive T-Lymphocytes, Male, Aging, Herpesvirus 3, Human, TRM, Resident memory T, CD8-Positive T-Lymphocytes, p38 Mitogen-Activated Protein Kinases, Article, Young Adult, CBA, Cytometric Bead Array, Humans, varicella zoster virus, Antigens, Viral, Aged, Skin, Aged, 80 and over, Inflammation, integumentary system, Interleukin-6, Tumor Necrosis Factor-alpha, p38 mitogen-activated protein kinase, Middle Aged, DC, Dendritic cell, MAP, Mitogen-activated protein, C-Reactive Protein, DEG, Differentially expressed gene, CRP, C-reactive protein, VZV, Varicella zoster virus, Female
Abstract

Background Immunity decreases with age, which leads to reactivation of varicella zoster virus (VZV). In human subjects age-associated immune changes are usually measured in blood leukocytes; however, this might not reflect alterations in tissue-specific immunity. Objectives We used a VZV antigen challenge system in the skin to investigate changes in tissue-specific mechanisms involved in the decreased response to this virus during aging. Methods We assessed cutaneous immunity based on the extent of erythema and induration after intradermal VZV antigen injection. We also performed immune histology and transcriptomic analyses on skin biopsy specimens taken from the challenge site in young (65 years) subjects. Results Old human subjects exhibited decreased erythema and induration, CD4+ and CD8+ T-cell infiltration, and attenuated global gene activation at the site of cutaneous VZV antigen challenge compared with young subjects. This was associated with increased sterile inflammation in the skin in the same subjects related to p38 mitogen-activated protein kinase–related proinflammatory cytokine production (P, Graphical abstract

Published
2018

213. Increase in TNF-[alpha] and inducible nitric oxide synthase-expressing dendritic cells in psoriasis and reduction with efalizumab (anti-CD11a)

Author

Lowes, Michelle A., Chamian, Francesca, Abello, Maria Veronica, Fuentes-Duculan, Judilyn, Lin, Shao-Lee, Nussbaum, Rachel, Novitskaya, Inna, Carbonaro, Henrietta, Cardinale, Irma, Kikuchi, Toyoko, Gilleaudeau, Patricia, Sullivan-Whalen, Mary, Wittkowski, Knut M., Papp, Kim, Garovoy, Marvin, Dummer, Wolfgang, Steinman, Ralph M., and Krueger, James G.

Subjects
Autoimmune diseases -- Diagnosis, Autoimmune diseases -- Research, Dendritic cells -- Research, Science and technology
Abstract

We find that CD[11c.sup.+] cells with many markers of dendritic cells (DCs) are a major cell type in the skin lesions of psoriasis. These CD[11c.sup.+] cells, which are evident in both epidermis and dermis, are the sites for the expression of two mediators of inflammation, inducible nitric oxide synthase (iNOS) and TNF-[alpha] in diseased skin. These cells express HLA-DR, CD40, and CD86, lack the Langerin and CD14 markers of Langerhans cells and monocytes, respectively, and to a significant extent express the DC maturation markers DC-LAMP and CD83. Treatment of psoriasis with efalizumab (antiCD11a, Raptiva) strongly reduces infiltration by these DCs in patients responding to this agent. Disease activity after therapy was more related to DC infiltrates and iNOS mRNA levels than T cell infiltrates, and CD[11c.sup.+] cells responded more quickly to therapy than epidermal keratinocytes. Our results suggest that a type of DC, which resembles murine 'Tip-DCs' that can accumulate during infection, has proinflammatory effects in psoriasis through nitric oxide and TNF-[alpha] production, and can be an important target for suppressive therapies. autoimrnune disease | CD11c | Tip-DC

Published
2005

217. 15340 Long-term treatment with secukinumab led to sustained clinical improvement and normalization of inflammatory markers in patients with psoriasis

Author

Krueger, James G., primary, Pariser, David, additional, Tyring, Stephen K., additional, Bagel, Jerry, additional, Alexis, Andrew F., additional, Soung, Jennifer, additional, Armstrong, April W., additional, Muscianisi, Elisa, additional, Kianifard, Farid, additional, Prasad Sarkar, Mr. Rajendra, additional, and Blauvelt, Andrew, additional

Published
2020
Full Text
View/download PDF

218. The erythema Q‐score, an imaging biomarker for redness in skin inflammation

Author

Frew, John, primary, Penzi, Lauren, additional, Suarez‐Farinas, Mayte, additional, Garcet, Sandra, additional, Brunner, Patrick M., additional, Czarnowicki, Tali, additional, Kim, Jaehwan, additional, Bottomley, Claire, additional, Finney, Robert, additional, Cueto, Inna, additional, Fuentes‐Duculan, Judilyn, additional, Ohmatsu, Hanako, additional, Lentini, Tim, additional, Yanofsky, Valerie, additional, Krueger, James G., additional, Guttman‐Yassky, Emma, additional, and Gareau, Daniel, additional

Published
2020
Full Text
View/download PDF

219. Deep learning-level melanoma detection by interpretable machine learning and imaging biomarker cues

Author

Gareau, Daniel S., primary, Browning, James, additional, Correa Da Rosa, Joel, additional, Suarez-Farinas, Mayte, additional, Lish, Samantha, additional, Zong, Amanda M., additional, Firester, Benjamin, additional, Vrattos, Charles, additional, Renert-Yuval, Yael, additional, Gamboa, Mauricio, additional, Vallone, María G., additional, Barragán-Estudillo, Zamira F., additional, Tamez-Peña, Alejandra L., additional, Montoya, Javier, additional, Jesús-Silva, Miriam A., additional, Carrera, Cristina, additional, Malvehy, Josep, additional, Puig, Susana, additional, Marghoob, Ashfaq, additional, Carucci, John A., additional, and Krueger, James G., additional

Published
2020
Full Text
View/download PDF

222. Pharmacokinetics and pharmacodynamics of multiple weekly subcutaneous Efalizumab doses in patients with plaque psoriasis

Author

Mortensen, Deborah L., Walicke, Patricia A., Wang, Xiaolin, Kwon, Paul, Kuebler, Peter, Gottlieb, Alice B., Krueger, James G., Leonardi, Craig, Miller, Bruce, and Joshi, Amita

Subjects
Psoriasis -- Drug therapy -- Research, Efalizumab -- Dosage and administration -- Research, Pharmacology -- Research, Health, Drug therapy, Research, Dosage and administration
Abstract

Efalizumab pharmacokinetics, pharmacodynamics, and efficacy were assessed after subcutaneous administration of 1.0 or 2.0 mg/kg/wk for 12 weeks with 12 weeks of follow-up in subjects with psoriasis. Steady-state serum concentrations [...]

Published
2005

229. Phase 2a randomized clinical trial of dupilumab (anti‐IL‐4Rα) for alopecia areata patients.

Author

Guttman‐Yassky, Emma, Renert‐Yuval, Yael, Bares, Jennifer, Chima, Margot, Hawkes, Jason E., Gilleaudeau, Patricia, Sullivan‐Whalen, Mary, Singer, Giselle K., Garcet, Sandra, Pavel, Ana B., Lebwohl, Mark G., and Krueger, James G.

Subjects
ALOPECIA areata, DUPILUMAB, MONOCLONAL antibodies, CLINICAL trials, PATIENT selection, HAIR transplantation, HAIR removal
Abstract

Background: Treatments for alopecia areata (AA) patients with extensive scalp hair loss are limited, and recent evidence supports a role for type 2 T‐cell (Th2)‐immune response in AA. Dupilumab, a monoclonal antibody inhibiting Th2 signaling, approved for type 2 diseases including atopic dermatitis, was evaluated in AA patients. Methods: Alopecia areata patients with and without concomitant atopic dermatitis were randomized 2:1 to receive weekly subcutaneous dupilumab (300 mg) or placebo for 24 weeks, followed by another 24‐week dupilumab open‐label phase. The primary outcome was change from baseline in the Severity of Alopecia Tool (SALT) score at week 24; secondary outcomes included a range of measures of hair regrowth. Results: Forty and 20 patients were assigned to the dupilumab and placebo arms, respectively. At week 24, disease worsening was documented in the placebo arm, with a least‐squares mean change in the SALT score of −6.5 (95% confidence‐interval [CI], −10.4 to −2.6), versus a change of 2.2 (95% CI, −0.6 to 4.94) in the dupilumab arm (p <.05). After 48 weeks of dupilumab treatment, 32.5%, 22.5% and 15% of patients achieved SALT30/SALT50/SALT75 improvement, respectively, while in patients with baseline IgE ≥ 200 IU/ml response rates increased to 53.8%, 46.2%, and 38.5%, respectively. Moreover, baseline IgE predicts treatment response with 83% accuracy. No new safety signals were detected. Conclusions: This hypothesis‐driven trial is the first to indicate the possible pathogenic role of the Th2 axis and Th2 targeting in AA patients. Patient selection based on baseline serum IgE levels may improve treatment results (Clinicaltrials.gov number, NCT03359356). [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

238. Tape strips from early‐onset pediatric atopic dermatitis highlight disease abnormalities in nonlesional skin

Author

Pavel, Ana B., primary, Renert‐Yuval, Yael, additional, Wu, Jianni, additional, Del Duca, Ester, additional, Diaz, Aisleen, additional, Lefferdink, Rachel, additional, Fang, Milie M., additional, Canter, Talia, additional, Rangel, Stephanie M., additional, Zhang, Ning, additional, Krueger, James G., additional, Paller, Amy S., additional, and Guttman‐Yassky, Emma, additional

Published
2020
Full Text
View/download PDF

240. Response to Inhibition of Receptor‐Interacting Protein Kinase 1 (RIPK1) in Active Plaque Psoriasis: A Randomized Placebo‐Controlled Study

Author

Weisel, Kathleen, primary, Berger, Scott, additional, Papp, Kim, additional, Maari, Catherine, additional, Krueger, James G., additional, Scott, Nicola, additional, Tompson, Debra, additional, Wang, Susanne, additional, Simeoni, Monica, additional, Bertin, John, additional, and Peter Tak, Paul, additional

Published
2020
Full Text
View/download PDF

241. A 3D biofabricated cutaneous squamous cell carcinoma tissue model with multi-channel confocal microscopy imaging biomarkers to quantify antitumor effects of chemotherapeutics in tissue

Author

Browning, James R., primary, Derr, Paige, additional, Derr, Kristy, additional, Doudican, Nicole, additional, Michael, Sam, additional, Lish, Samantha R., additional, Taylor, Nicholas A., additional, Krueger, James G., additional, Ferrer, Marc, additional, Carucci, John A., additional, and Gareau, Daniel S., additional

Published
2020
Full Text
View/download PDF

244. Persistence of Inflammatory Phenotype in Residual Psoriatic Plaques in Patients on Effective Biologic Therapy

Author

Mashiko, Shunya, primary, Edelmayer, Rebecca M., additional, Bi, Yingtao, additional, Olson, Lauren M., additional, Wetter, Joseph B., additional, Wang, Jing, additional, Maari, Catherine, additional, Saint-Cyr Proulx, Etienne, additional, Kaimal, Vivek, additional, Li, Xuan, additional, Salte, Katherine, additional, Garcet, Sandra, additional, Kannan, Arun K., additional, Huang, Susan M., additional, Cao, Xiaohong, additional, Liu, Zheng, additional, Krueger, James G., additional, Sarfati, Marika, additional, Bissonnette, Robert, additional, and Smith, Kathleen M., additional

Published
2020
Full Text
View/download PDF

245. Activated Platelets Induce Endothelial Cell Inflammatory Response in Psoriasis via COX-1

Author

Garshick, Michael S., primary, Tawil, Michael, additional, Barrett, Tessa J., additional, Salud-Gnilo, Charissa M., additional, Eppler, Michael, additional, Lee, Angela, additional, Scher, Jose U., additional, Neimann, Andrea L., additional, Jelic, Sanja, additional, Mehta, Nehal N., additional, Fisher, Edward A., additional, Krueger, James G., additional, and Berger, Jeffrey S., additional

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results